<DOC>
	<DOCNO>NCT03083639</DOCNO>
	<brief_summary>The purpose study determine bioequivalence esomeprazole 40 milligram ( mg ) tablets capsule .</brief_summary>
	<brief_title>A Study Evaluate Bioequivalence Single Oral Dose Esomeprazole Capsule Tablet Formulation Healthy Participants</brief_title>
	<detailed_description>The drug test study call esomeprazole . Esomeprazole test healthy participant order evaluate bioequivalence single oral dose esomeprazole tablet capsule . The study enroll 52 participant . Participants randomly assign ( chance , like flip coin ) one two treatment sequence : - Esomeprazole 40 mg capsule + Esomeprazole 40 mg tablet - Esomeprazole 40 mg tablet + Esomeprazole 40 mg capsule All participants ask take one capsule tablet Day 1 Intervention Period base treatment sequence participant assign . This single center trial conduct United States . The overall duration participate study 36 day . Participants visit clinic Day -1 remain confined Day 1 Intervention Period 1 2 . A washout period minimum 6 day maintain dose Intervention Period .</detailed_description>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>1 . Is healthy adult male female participant . 2 . Is age 18 55 year , inclusive , time informed consent first study medication dose . 3 . Weighs least 50 kilogram ( kg ) body mass index ( BMI ) 18.5 30 kilogram per square meter ( kg/m^2 ) , inclusive Screening Day 1 . 1 . Has uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , endocrine disease abnormality , may impact ability participant participate potentially confound study result . It responsibility investigator assess clinical significance ; however , consultation Takeda Medical Monitor may warrant . 2 . Has history significant gastro intestinal ( GI ) disorder manifest persistent , chronic intermittent nausea , vomit , diarrhea , current recent ( within 6 month ) GI disease would influence absorption drug ( example , history malabsorption , severe esophageal reflux , peptic ulcer disease erosive esophagitis ) , gastrointestinalrelated surgical intervention.. 3 . Has know hypersensitivity component formulation esomeprazole capsule tablet compound mechanism action ( dexlansoprazole , lansoprazole , omeprazole , rabeprazole , pantoprazole ) , related compound .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>